Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases

Core Insights - Arvinas, Inc. is set to present data from its first-in-human study of ARV-102, a drug targeting LRRK2, at the International Conference on Alzheimer's and Parkinson's Diseases in April 2025 [1][3] - ARV-102 is designed as a PROTAC to degrade LRRK2, which is linked to Parkinson's disease and progressive supranuclear palsy [2][4] - The presentation will focus on the safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy males [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies for serious diseases using its PROTAC platform [5] - The company is advancing multiple investigational drugs, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5] - Arvinas is headquartered in New Haven, Connecticut, and aims to improve patient outcomes through innovative protein degradation therapies [5]